Short Information | Vor Biopharma Inc. (NASDAQ:VOR)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 1,499,317 |
Total Actual Volume | 10,599,987 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 74,966 |
Average Short Percentage | 20.16% |
Is there a VOR Short Squeeze or Breakout about to happen?
See the VOR Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-02-2024 | $0.98 | $0.914 | $0.98 | $0.9 | 359,976 | 79,586 | 22.11% |
07-01-2024 | $1.03 | $0.9893 | $1.09 | $0.9134 | 433,502 | 134,469 | 31.02% |
06-28-2024 | $1.16 | $1 | $1.16 | $1 | 4,721,857 | 248,809 | 5.27% |
06-27-2024 | $1.15 | $1.14 | $1.17 | $1.11 | 379,846 | 116,075 | 30.56% |
06-26-2024 | $1.26 | $1.15 | $1.27 | $1.15 | 313,807 | 80,246 | 25.57% |
06-25-2024 | $1.22 | $1.24 | $1.24 | $1.2 | 716,593 | 50,728 | 7.08% |
06-24-2024 | $1.18 | $1.24 | $1.27 | $1.18 | 222,065 | 32,765 | 14.75% |
06-21-2024 | $1.2 | $1.19 | $1.225 | $1.165 | 313,235 | 51,320 | 16.38% |
06-20-2024 | $1.19 | $1.2 | $1.21 | $1.16 | 135,467 | 24,776 | 18.29% |
06-18-2024 | $1.18 | $1.2 | $1.27 | $1.1704 | 230,256 | 40,189 | 17.45% |
06-17-2024 | $1.15 | $1.17 | $1.18 | $1.11 | 336,145 | 33,820 | 10.06% |
06-14-2024 | $1.22 | $1.15 | $1.22 | $1.11 | 353,797 | 97,827 | 27.65% |
06-13-2024 | $1.27 | $1.2 | $1.27 | $1.18 | 341,918 | 112,078 | 32.78% |
06-12-2024 | $1.29 | $1.26 | $1.3 | $1.24 | 242,123 | 54,705 | 22.59% |
06-11-2024 | $1.29 | $1.25 | $1.32 | $1.225 | 266,865 | 62,911 | 23.57% |
06-10-2024 | $1.2 | $1.3 | $1.3 | $1.2 | 243,345 | 42,861 | 17.61% |
06-07-2024 | $1.25 | $1.225 | $1.26 | $1.22 | 137,257 | 11,787 | 8.59% |
06-06-2024 | $1.29 | $1.265 | $1.3 | $1.17 | 362,370 | 112,666 | 31.09% |
06-05-2024 | $1.33 | $1.31 | $1.36 | $1.29 | 178,795 | 20,582 | 11.51% |
06-04-2024 | $1.43 | $1.32 | $1.45 | $1.28 | 310,768 | 91,117 | 29.32% |
News, Short Squeeze, Breakout and More Instantly...
On-track for trem-cel and VCAR33 ALLO clinical updates in the second half of 2024 Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWI...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint M...
Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March...